Septerna, Inc.

NasdaqGM:SEPN Stock Report

Market Cap: US$1.1b

Septerna Management

Management criteria checks 4/4

Septerna's CEO is Jeff Finer, appointed in Nov 2021, has a tenure of 4.5 years. total yearly compensation is $2.93M, comprised of 21.6% salary and 78.4% bonuses, including company stock and options. directly owns 1.84% of the company’s shares, worth $19.74M. The average tenure of the management team and the board of directors is 3.6 years and 3.4 years respectively.

Key information

Jeff Finer

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage21.65%
CEO tenure4.5yrs
CEO ownership1.8%
Management average tenure3.6yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

Seeking Alpha • Nov 25

Septerna's Novo Partnership Begins To Transform The Story

Summary Septerna, Inc. delivered a strong 3Q25, driven by partnership revenue from its transformative collaboration with Novo Nordisk. SEPN's Novo partnership brings $195M upfront, a potential $2.2B in milestones, and full R&D funding, reducing capital burden and boosting strategic position. The incretin-pathway GPCR program is closest to early milestones, with further upside tied to successful target validation and hit-to-lead advancements. Despite elevated valuation multiples, SEPN's robust cash position and pipeline progress support a bullish outlook, though volatility and long timelines remain. Read the full article on Seeking Alpha
Analysis Article • Oct 05

We're Not Worried About Septerna's (NASDAQ:SEPN) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Apr 28

Companies Like Septerna (NASDAQ:SEPN) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 04

Septerna: Great In Theory, Needs Proof

Summary Septerna's Native Complex platform isolates GPCRs in their native form, enabling advanced drug discovery for previously undruggable targets, including oral small-molecule therapeutics. Lead molecule SEP-786 targets hypoparathyroidism, showing promising preclinical results and entering phase 1 trials, with data expected in mid-2025. SEPN has a $750mn market cap and $130mn in cash, providing a 6-7 quarter runway, but lacks clinical data until 2025. Despite the innovative platform, I recommend waiting for phase 1 data before investing due to the current lack of clinical proof. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Jeff Finer's remuneration changed compared to Septerna's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$3mUS$635k

-US$49m

Sep 30 2025n/an/a

-US$59m

Jun 30 2025n/an/a

-US$88m

Mar 31 2025n/an/a

-US$79m

Dec 31 2024US$5mUS$550k

-US$72m

Sep 30 2024n/an/a

-US$20m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$2mUS$501k

US$567k

Compensation vs Market: Jeff's total compensation ($USD2.93M) is about average for companies of similar size in the US market ($USD3.72M).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.

CEO

Jeff Finer (58 yo)

4.5yrs
Tenure
US$2,933,339
Compensation

Dr. Jeffrey T. Finer, also known as Jeff, M.D. & Ph D., serves as Consultant of Kainomyx, Inc. He is Co-Founder & Director of Septerna, Inc. and serves as its Chief Executive Officer from September 2022 an...

Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Finer
Co-Founder4.5yrsUS$2.93m1.84%
$ 19.7m
Elizabeth Bhatt
President & COO3.9yrsUS$1.59m0.39%
$ 4.2m
Gilbert Labrucherie
Chief Financial Officer1.3yrsUS$3.25m0.089%
$ 954.8k
Robert Lefkowitz
Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Boardno datano datano data
Arthur Christopoulos
Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Boardno datano datano data
Patrick Sexton
Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Boardno datano datano data
Richard Hansen
Vice President of Technologyno datano datano data
Mark Wilson
Chief Legal Officerless than a yearno datano data
George Xu
Senior Director of Corporate Development & Portfolio Strategy3.3yrsno datano data
Samira Shaikhly
Chief People Officer3.3yrsUS$771.85k0.0018%
$ 19.0k
Daniel Long
Senior Vice President of Drug Discovery4.6yrsUS$646.74k0.21%
$ 2.2m
Uwe Klein
Senior Vice President of Biological Sciences4.8yrsUS$578.53k0.28%
$ 3.0m
3.6yrs
Average Tenure
56yo
Average Age

Experienced Management: SEPN's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Finer
Co-Founder4.5yrsUS$2.93m1.84%
$ 19.7m
Robert Lefkowitz
Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board3.4yrsno datano data
Arthur Christopoulos
Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board3.4yrsno datano data
Patrick Sexton
Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board3.4yrsno datano data
Shalini Sharp
Independent Director2.3yrsUS$185.90k0%
$ 0
Jeffrey Tong
Chairman of the Board6.4yrsUS$202.40k0%
$ 0
Bernard Coulie
Independent Director2.4yrsUS$183.73k0%
$ 0
Alan Ezekowitz
Director3.4yrsUS$285.73k0.26%
$ 2.8m
Aashish Manglik
Member of Cross-Functional Scientific & Drug Discovery Advisory Board3.4yrsno datano data
Abraham Bassan
Independent Director4.5yrsUS$182.40k0%
$ 0
Bryan Roth
Member of Cross-Functional Scientific & Drug Discovery Advisory Board3.4yrsno datano data
Denise Wootten
Member of Cross-Functional Scientific & Drug Discovery Advisory Board3.4yrsno datano data
3.4yrs
Average Tenure
58yo
Average Age

Experienced Board: SEPN's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/11 12:38
End of Day Share Price 2026/05/11 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Septerna, Inc. is covered by 9 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.
Catherine NovackJonesTrading Institutional Services, LLC